Piper Sandler Increases Kenvue (NYSE:KVUE) Price Target to $21.00

Kenvue (NYSE:KVUE) had its target price raised by equities researchers at Piper Sandler from $20.00 to $21.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Piper Sandler’s target price would indicate a potential downside of 9.13% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. Citigroup dropped their price objective on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 target price on shares of Kenvue in a research report on Wednesday, August 7th. JPMorgan Chase & Co. boosted their price objective on shares of Kenvue from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, UBS Group boosted their target price on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $22.10.

Kenvue Trading Up 0.4 %

Kenvue stock opened at $23.11 on Monday. The stock has a market capitalization of $44.25 billion, a PE ratio of 29.63, a price-to-earnings-growth ratio of 2.92 and a beta of 1.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. The business’s fifty day moving average is $21.12 and its 200 day moving average is $20.01. Kenvue has a one year low of $17.67 and a one year high of $23.55.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The business had revenue of $4 billion during the quarter, compared to the consensus estimate of $3.93 billion. During the same quarter last year, the firm earned $0.32 earnings per share. The firm’s quarterly revenue was down .3% compared to the same quarter last year. On average, sell-side analysts predict that Kenvue will post 1.08 EPS for the current year.

Institutional Trading of Kenvue

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KVUE. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in Kenvue by 18.7% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 4,857,910 shares of the company’s stock worth $88,317,000 after purchasing an additional 763,738 shares during the last quarter. Clifford Capital Partners LLC increased its holdings in shares of Kenvue by 21.3% in the second quarter. Clifford Capital Partners LLC now owns 788,451 shares of the company’s stock valued at $14,334,000 after buying an additional 138,203 shares in the last quarter. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group lifted its holdings in shares of Kenvue by 9.4% during the second quarter. Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group now owns 67,723 shares of the company’s stock valued at $1,231,000 after purchasing an additional 5,810 shares during the last quarter. Sanctuary Advisors LLC purchased a new stake in Kenvue during the second quarter valued at about $3,859,000. Finally, Ghisallo Capital Management LLC boosted its holdings in shares of Kenvue by 200.0% in the second quarter. Ghisallo Capital Management LLC now owns 3,000,000 shares of the company’s stock worth $54,540,000 after buying an additional 2,000,000 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.